Genzyme received a double dose of bad news on February 27th when the US FDA issued complete response and warning letters delaying approval of Lumizyme, a version of the Pompe disease treatment Myozyme (alglucosidase alfa) produced at a larger manufacturing scale, by as much as six months.
The company and agency failed to reach agreement before the February 28th user fee deadline on a post-marketing verification study, risk evaluation and mitigation strategy (REMS) and labelling, thus resulting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?